Myxedema Coma or Crisis
- Author: Mohsen S Eledrisi, MD, FACP, FACE; Chief Editor: George T Griffing, MD more...
Myxedema is a term generally used to denote severe hypothyroidism. Myxedema is also used to describe the dermatologic changes that occur in hypothyroidism and occasionally hyperthyroidism. In this setting, myxedema refers to deposition of mucopolysaccharides in the dermis, which results in swelling of the affected area. When skin changes occur in hyperthyroidism, mostly Graves disease, it’s called pretibial myxedema.
Myxedema coma, occasionally called myxedema crisis, is a rare life-threatening clinical condition that represents severe hypothyroidism with physiological decompensation.[1, 2] The condition usually occurs in patients with long-standing, undiagnosed hypothyroidism and is usually precipitated by infection, cerebrovascular disease, heart failure, trauma, or drug therapy. Patients with myxedema coma are generally severely-ill with significant hypothermia and depressed mental status.
A medical emergency, myxedema coma requires immediate attention. If the diagnosis is suspected, immediate management is necessary before confirming the diagnosis due to the high associated mortality rate. Patients with myxedema coma should be treated in an intensive care unit with continuous cardiac monitoring. Initial steps in therapy include airway management, thyroid hormone replacement, glucocorticoid therapy, and supportive measures.
Myxedema coma occurs as a result of long-standing, undiagnosed, or undertreated hypothyroidism and is usually precipitated by a systemic illness. Myxedema coma can result from any of the causes of hypothyroidism, most commonly chronic autoimmune thyroiditis. It can also occur in patients who had thyroidectomy or underwent radioactive iodine therapy for hyperthyroidism. Rare causes may include secondary hypothyroidism and medications such as lithium and amiodarone.[3, 4]
Given the importance of thyroid hormones in cell metabolism, long-standing hypothyroidism is associated with reduced metabolic rate and decreased oxygen consumption, which affects all body systems. This results in hypothermia, which is a strong predictor of mortality. Another consequence is decreased drug metabolism leading to overdosing of medications particularly sedatives, hypnotics, and anesthetic agents; this can precipitate myxedema coma.
Cardiac contractility is impaired, leading to reduced stroke volume, low cardiac output, bradycardia and sometimes hypotension. Reduced stroke volume in severe cases may also be due to pericardial effusions caused by the accumulation of fluid rich in mucopolysaccharides within the pericardial sac. Congestive heart failure is rarely seen in the absence of preexisting cardiac disease.
Electrocardiographic findings may include bradycardia, varying degrees of block, low voltage, nonspecific ST-segment changes, flattened or inverted T waves, prolonged Q-T interval, and ventricular or atrial arrhythmias.
The reduction of the effect of beta-adrenergic receptors leads to prevalence of the effect of alpha-adrenergic receptors, increased catecholamines, and increased systemic vascular resistance, causing some patients to have diastolic hypertension and a narrowed pulse pressure.
Plasma volume is decreased, and capillary permeability is increased, leading to fluid accumulation in tissue and spaces and pericardial effusions.
Despite the term myxedema coma, many patients do not present in coma, but manifest variable degrees of altered consciousness. Brain function is affected by reduction in oxygen delivery and subsequent consumption, decreased glucose utilization and reduced cerebral blood flow. Hyponatremia can also contribute to altered mental function.
The main pulmonary effect of myxedema coma is hypoventilation, which results from central depression of ventilatory drive with decreased responsiveness to hypoxia and hypercapnia.[9, 10] Other contributing factors to hypoventilation include respiratory muscle weakness, mechanical obstruction by a large tongue, and obesity-hypoventilation syndrome. Fluid accumulation may cause pleural effusions and decreased diffusing capacity.
Kidney function may be compromised with reduced glomerular filtration rate because of low cardiac output and peripheral vasoconstriction or because of rhabdomyolysis.[11, 12] Hyponatremia is common in patients with myxedema coma and is caused by increased serum antidiuretic hormone and impaired water excretion.[13, 14]
The gastrointestinal tract in myxedema coma can be marked by mucopolysaccharide infiltration and edema. In addition, neuropathic changes can cause malabsorption, gastric atony, impaired peristalsis, paralytic ileus, and megacolon. Ascites may occur due to increased capillary permeability, heart failure, or other mechanisms. Gastrointestinal bleeding secondary to an associated coagulopathy may occur.
Myxedema coma is associated with a higher risk of bleeding caused by coagulopathy related to an acquired von Willebrand syndrome (type 1) and decreases in factors V, VII, VIII, IX, and X.[18, 19] Patients may also have microcytic anemia secondary to hemorrhage, or macrocytic anemia caused by vitamin B12 deficiency, or normocytic normochromic anemia, which may be secondary to decreased oxygen requirement and reduced erythropoietin.
Myxedema coma is a rare consequence of untreated hypothyroidism, and the exact prevalence in the United States is not known.
A report from Spain showed that the incidence rate of myxedema coma is 0.22 per million per year.
Myxedema coma is a medical emergency. If the condition is not promptly diagnosed and treated, the mortality rate can be more than 50%. Even with immediate recognition and timely medical intervention, mortality rates are as high as 25%.
The most common causes of death are respiratory failure, sepsis, and gastrointestinal bleeding.
Myxedema coma carries a high mortality and morbidity rate. Therefore, timely recognition and proper management is critical. Factors suggesting a poor prognosis are older age, persistent hypothermia, or bradycardia, lower degree of consciousness by Glasgow Coma Scale, multiorgan impairment indicated by high APACHE (Acute Physiology and Chronic Health Evaluation) II score.[21, 22, 23, 24]
Patients who are diagnosed with hypothyroidism should be counseled regarding the necessity of taking daily thyroid hormone replacement and monitoring of thyroid tests on a regular basis.
Patients with a history of thyroiditis or who have undergone thyroid irradiation or thyroid surgery should be counseled that hypothyroidism might occur in the future. They should be educated about the symptoms of hypothyroidism and should understand the importance of seeking timely medical advice for examination and testing.
Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. 2007 Jul-Aug. 22(4):224-31. [Medline].
Klubo-Gwiezdzinska J, Wartofsky L. Thyroid emergencies. Med Clin North Am. 2012 Mar. 96(2):385-403. [Medline].
Waldman SA, Park D. Myxedema coma associated with lithium therapy. Am J Med. 1989 Sep. 87 (3):355-6. [Medline].
Mazonson PD, Williams ML, Cantley LK, Dalldorf FG, Utiger RD, Foster JR. Myxedema coma during long-term amiodarone therapy. Am J Med. 1984 Oct. 77 (4):751-4. [Medline].
Nicoloff JT, LoPresti JS. Myxedema coma. A form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. 1993 Jun. 22(2):279-90. [Medline].
Klein I. Thyroid hormone and the cardiovascular system. Am J Med. 1990 Jun. 88 (6):631-7. [Medline].
Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. Am J Med Sci. 2006 Mar. 331 (3):154-6. [Medline].
Mathew V, Misgar RA, Ghosh S, Mukhopadhyay P, Roychowdhury P, Pandit K, et al. Myxedema coma: a new look into an old crisis. J Thyroid Res. 2011. 2011:493462. [Medline]. [Full Text].
Zwillich CW, Pierson DJ, Hofeldt FD, Lufkin EG, Weil JV. Ventilatory control in myxedema and hypothyroidism. N Engl J Med. 1975 Mar 27. 292 (13):662-5. [Medline].
Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med. 1988 May. 84 (5):877-83. [Medline].
Ardalan MR, Ghabili K, Mirnour R, Shoja MM. Hypothyroidism-induced rhabdomyolysis and renal failure. Ren Fail. 2011. 33 (5):553-4. [Medline].
Birewar S, Oppenheimer M, Zawada ET Jr. Hypothyroid acute renal failure. S D J Med. 2004 Mar. 57 (3):109-10. [Medline].
Skowsky WR, Kikuchi TA. The role of vasopressin in the impaired water excretion of myxedema. Am J Med. 1978 Apr. 64 (4):613-21. [Medline].
Derubertis FR Jr, Michelis MF, Bloom ME, Mintz DH, Field JB, Davis BB. Impaired water excretion in myxedema. Am J Med. 1971 Jul. 51 (1):41-53. [Medline].
Bergeron E, Mitchell A, Heyen F, Dube S. Acute colonic surgery and unrecognized hypothyroidism: a warning. Report of six cases. Dis Colon Rectum. 1997 Jul. 40 (7):859-61. [Medline].
Ji JS, Chae HS, Cho YS, Kim HK, Kim SS, et al. Myxedema ascites: case report and literature review. J Korean Med Sci. 2006 Aug. 21 (4):761-4. [Medline].
Fukunaga K. Refractory gastrointestinal bleeding treated with thyroid hormone replacement. J Clin Gastroenterol. 2001 Aug. 33 (2):145-7. [Medline].
Manfredi E, van Zaane B, Gerdes VE, Brandjes DP, Squizzato A. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review. Haemophilia. 2008 May. 14 (3):423-33. [Medline].
Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgrad Med J. 1990 Apr. 66 (774):280-4. [Medline].
Rodriguez I, Fluiters E, Perez-Mendez LF, et al. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol. 2004 Feb. 180(2):347-50. [Medline]. [Full Text].
Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008. 12(1):R1. [Medline]. [Full Text].
Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid. 1999 Dec. 9(12):1167-74. [Medline].
Hylander B, Rosenqvist U. Treatment of myxoedema coma--factors associated with fatal outcome. Acta Endocrinol (Copenh). 1985 Jan. 108(1):65-71. [Medline].
Jordan RM. Myxedema coma. Pathophysiology, therapy, and factors affecting prognosis. Med Clin North Am. 1995 Jan. 79(1):185-94. [Medline].
Popoveniuc G, Chandra T, Sud A, Sharma M, Blackman MR, Burman KD, et al. A diagnostic scoring system for myxedema coma. Endocr Pract. 2014 Aug 1. 20(8):808-17. [Medline].
Chiong YV, Bammerlin E, Mariash CN. Development of an objective tool for the diagnosis of myxedema coma. Transl Res. 2015 Sep. 166 (3):233-43. [Medline].
MacKerrow SD, Osborn LA, Levy H, Eaton RP, Economou P. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Ann Intern Med. 1992 Dec 15. 117 (12):1014-5. [Medline].
Arlot S, Debussche X, Lalau JD, Mesmacque A, Tolani M, Quichaud J, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med. 1991. 17 (1):16-8. [Medline].
Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec. 24 (12):1670-751. [Medline].
Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine. Ann Intern Med. 1972 Oct. 77 (4):549-55. [Medline].
Fliers E, Wiersinga WM. Myxedema coma. Rev Endocr Metab Disord. 2003 May. 4(2):137-41. [Medline].
Dutta P, Bhansali A, Masoodi SR, Bhadada S, Sharma N, Rajput R. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008. 12(1):R1. [Medline]. [Full Text].